WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
Bio-Europe
-
PEGS Europe
-
Cancer Research Horizons Innovation Summit
-
Oxford-Cambridge Innovation Showcase 2025
Optibrium Delivers Real-Time Collaboration in its Comprehensive Molecular Design Platform with StarDrop 8
Latest release accelerates hit-to-candidate progression by keeping teams aligned, eliminating inefficiencies and enabling better prioritisation decisions CAMBRIDGE, UK, 04 November 2025 – Optibrium, a leading developer of software and AI [...]
Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia and New Zealand
Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion Cambridge, UK, and Boston MA, USA, 03 November 2025: Nuclera, the biotechnology company accelerating drug discovery by [...]
VALANX Biotech appoints Klaus Orlinger, PhD. as Chief Scientific Officer
Strategic hire of industry expert bolsters leadership team as Company progresses first antibody drug conjugate to candidate selection phase Appointment will drive development of VALANX’ GoldenSite™ platform to advance development [...]




















